Jessica N. Becerra

Jessica N. Becerra

Auto-generated profile, based on publicly available information

Jessica N. Becerra

Translational Research Program, Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2025 in Cancer Research Communications
Verified
Journal Article
Open access
NGNina Marie G. Garcia
Nina Marie G. Garcia
JBJessica N. Becerra
Jessica N. Becerra
SSSharan Srinivasan
Sharan Srinivasan
BMBrock J. McKinney
Brock J. McKinney
ADAshley V. DiMarco
Ashley V. DiMarco
JAJames V. Alvarez
James V. Alvarez
APOBEC mutagenesis is one of the most common endogenous sources of mutations in human cancer and is a major source of genetic intratumor heterogeneity. High levels of APOBEC mutagenesis are associated with poor prognosis and aggressive disease across diverse cancers, but the mechanistic and functional impacts of APOBEC mutagenesis on tumor evolution and therapy resistance remain relatively unexplored. To address this, we investigated the contribution of APOBEC mutagenesis to acquired therapy resistance in a model of EGFR-mutant non–small cell lung cancer. We find that inhibition of EGFR in lung cancer cells leads to a rapid and pronounced induction of APOBEC3 expression and activity. Functionally, APOBEC expression promotes the survival of drug-tolerant persister cells (DTP) following EGFR inhibition. Constitutive expression of APOBEC3B alters the evolutionary trajectory of acquired resistance to the EGFR inhibitor gefitinib, making it more likely that resistance arises through de novo acquisition of the T790M gatekeeper mutation and squamous transdifferentiation during the DTP state. APOBEC3B expression is associated with increased expression of the squamous cell transcription factor ΔNp63 and squamous cell transdifferentiation in gefitinib-resistant cells. Knockout of p63 in gefitinib-resistant cells reduces the expression of the ΔNp63 target genes IL-1α/β and sensitizes these cells to the third-generation EGFR inhibitor osimertinib. These results suggest that APOBEC activity promotes acquired resistance by facilitating evolution and transdifferentiation in DTPs and that approaches to target ΔNp63 in gefitinib-resistant lung cancers may have therapeutic benefit. Significance: APOBEC mutagenesis is a common source of genetic heterogeneity in cancer, and APOBEC mutational signatures are enriched in metastatic and drug-resistant tumors. However, the mechanisms through which APOBEC3 enzymes promote tumor evolution remain unknown. In this study, we show that APOBEC3 activity contributes to the development of therapy-resistant cancer cells by promoting evolution of DTP cells. These findings offer insights into the role of APOBEC mutagenesis in cancer progression.

21 May 2025
Verified
Other
Open access
NGNina Marie G. Garcia
Nina Marie G. Garcia
JBJessica N. Becerra
Jessica N. Becerra
SSSharan Srinivasan
Sharan Srinivasan
BMBrock J. McKinney
Brock J. McKinney
ADAshley V. DiMarco
Ashley V. DiMarco
JAJames V. Alvarez
James V. Alvarez
APOBEC expression is partially regulated by NFkappaB and STAT1.

21 May 2025
Verified
Other
Open access
NGNina Marie G. Garcia
Nina Marie G. Garcia
JBJessica N. Becerra
Jessica N. Becerra
SSSharan Srinivasan
Sharan Srinivasan
BMBrock J. McKinney
Brock J. McKinney
ADAshley V. DiMarco
Ashley V. DiMarco
JAJames V. Alvarez
James V. Alvarez
Developing resistance to gefitinib in A3B-off and A3B-on PC9 cells.

21 May 2025
Verified
Other
Open access
NGNina Marie G. Garcia
Nina Marie G. Garcia
JBJessica N. Becerra
Jessica N. Becerra
SSSharan Srinivasan
Sharan Srinivasan
BMBrock J. McKinney
Brock J. McKinney
ADAshley V. DiMarco
Ashley V. DiMarco
JAJames V. Alvarez
James V. Alvarez
P63 knockout reduces inflammatory gene expression and sensitizes PC9 GR cells to EGFR inhibition. A, Dose–response curve of osimertinib in gefitinib-sensitive and GR PC9 cells expressing A3B. Viability was measured using CellTiter Glo following 3 days of drug treatment. A two-way ANOVA with the Tukey multiple comparisons test was used to determine statistical significance at each dose. ****, P < 0.0001 when comparing PC9 A3B-on GRF and GRE cells at the indicated dose. B, Western blots for pEGFR (Y1068) and total EGFR in gefitinib-sensitive and GR PC9 cells expressing A3B. Cells were treated with osimertinib (Osi) for 24 hours. C, Western blots for p63α in PC9 A3B-on GRF cells expressing an empty vector or gRNAs targeting p63 (sg1 and sg3). PC9 A3B-on F cells are shown as a control. D, qRT-PCR analysis showing IL-1A and IL-1B expression in PC9 A3B-on GRF cells expressing an empty vector or gRNAs targeting p63 (sg1 and sg3). PC9 A3B-on F cells are shown as a control. Error bars represent SEM of three technical replicates. An unpaired t test was performed to determine statistical significance. **, P < 0.005; ****, P < 0.0001. E, In vitro growth curves of PC9 A3B-on GRF cells with or without p63 knockout. A two-way ANOVA was performed to determine statistical significance. ns, not significant. F, Dose–response curve of osimertinib in PC9 A3B-on GRF cells expressing an empty vector or gRNAs targeting p63 (sg1 and sg3). Viability was measured using CellTiter Glo following 3 days of drug treatment. A two-way ANOVA was performed, which determined a significant p63 status × dose interaction with a P value of 0.02. G, Viability of PC9 A3B-on GRF cells expressing an empty vector or gRNAs targeting p63 (sg1 and sg3) following treatment with osimertinib for 6 days. A two-way ANOVA with the Dunnett test was performed to determine statistical significance. ****, P < 0.00001. H, Model for the function of APOBEC3 in the survival and evolution of DTP cells during acquired resistance to EGFR inhibition. EGFR inhibition leads to STAT1-dependent upregulation of A3A and A3B. The expression of A3A and A3B is required for the survival of DTPs and is associated with an increased frequency of ∆Np63 upregulaiton and squamous transdifferentiation in the drug-resistant state. ∆Np63 expression in drug-resistant cells promotes osimertinib resistance in part through upregulation of EGFR ligands.

21 May 2025
Verified
Other
Open access
NGNina Marie G. Garcia
Nina Marie G. Garcia
JBJessica N. Becerra
Jessica N. Becerra
SSSharan Srinivasan
Sharan Srinivasan
BMBrock J. McKinney
Brock J. McKinney
ADAshley V. DiMarco
Ashley V. DiMarco
JAJames V. Alvarez
James V. Alvarez
Integrated genomic analysis of GR PC9 cells. A, Quantification of mutations per exome in A3B-off and A3B-on GR cells. Mutations were called as described in “Materials and Methods”. B, PCA from RNA-seq data. C, Gene set enrichment analysis comparing A3B-on and A3B-off sensitive PC9 cells.

21 May 2025
Verified
Other
Open access
NGNina Marie G. Garcia
Nina Marie G. Garcia
JBJessica N. Becerra
Jessica N. Becerra
SSSharan Srinivasan
Sharan Srinivasan
BMBrock J. McKinney
Brock J. McKinney
ADAshley V. DiMarco
Ashley V. DiMarco
JAJames V. Alvarez
James V. Alvarez
Trinucleotide contexts of mutations in gefitinib-sensitive and gefitinib-resistant PC9 cells with and without A3B expression.